Avanos Medical, Inc.
NYSE:AVNS
19.49 (USD) • At close November 13, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 673.3 | 820 | 744.6 | 714.8 | 697.6 | 652.3 | 611.6 | 1,592.3 | 1,574.4 | 1,672.1 | 1,677.5 | 1,684 | 1,659.9 |
| Cost of Revenue
| 293.6 | 370 | 380.3 | 341.5 | 295.4 | 261.4 | 274.7 | 1,034.4 | 1,042.8 | 1,123.5 | 1,065.3 | 1,081.5 | 1,069.1 |
| Gross Profit
| 379.7 | 450 | 364.3 | 373.3 | 402.2 | 390.9 | 336.9 | 557.9 | 531.6 | 548.6 | 612.2 | 602.5 | 590.8 |
| Gross Profit Ratio
| 0.564 | 0.549 | 0.489 | 0.522 | 0.577 | 0.599 | 0.551 | 0.35 | 0.338 | 0.328 | 0.365 | 0.358 | 0.356 |
| Reseach & Development Expenses
| 27.2 | 30.6 | 32.3 | 34.9 | 37.7 | 41.8 | 38.2 | 41.1 | 32.3 | 33.6 | 37.9 | 33 | 31.2 |
| General & Administrative Expenses
| 0 | 0 | 0 | 0 | 0 | 340.4 | 321.7 | 411.1 | 398.5 | 424.5 | 351.4 | 343 | 351.7 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 318.1 | 341.9 | 300.3 | 332.6 | 399.1 | 340.4 | 321.7 | 411.1 | 398.5 | 424.5 | 351.4 | 343 | 351.7 |
| Other Expenses
| 0 | 3.5 | 22.8 | 51.9 | 21.1 | 8.2 | 20.1 | 18.3 | 4.5 | -3.8 | -2.4 | -1.5 | -2.8 |
| Operating Expenses
| 330.3 | 376 | 355.4 | 419.4 | 457.9 | 390.4 | 380 | 470.5 | 435.3 | 454.3 | 386.9 | 374.5 | 380.1 |
| Operating Income
| 4.2 | 74 | 8.9 | -46.1 | -55.7 | 0.5 | -43.1 | 87.4 | -377.7 | 94.3 | 225.3 | 228 | 210.7 |
| Operating Income Ratio
| 0.006 | 0.09 | 0.012 | -0.064 | -0.08 | 0.001 | -0.07 | 0.055 | -0.24 | 0.056 | 0.134 | 0.135 | 0.127 |
| Total Other Income Expenses Net
| -12.1 | -8.8 | -3.1 | -14.4 | -8.3 | -18.6 | -29.1 | -18.3 | -474 | 3.8 | 2.5 | 1.8 | 3.9 |
| Income Before Tax
| -7.9 | 65.2 | 5.8 | -60.5 | -64 | -18.1 | -72.2 | 55.3 | -410.5 | 91.2 | 227.8 | 229.8 | 214.6 |
| Income Before Tax Ratio
| -0.012 | 0.08 | 0.008 | -0.085 | -0.092 | -0.028 | -0.118 | 0.035 | -0.261 | 0.055 | 0.136 | 0.136 | 0.129 |
| Income Tax Expense
| 2 | 14.7 | 0.6 | -33.3 | -18.1 | -9.6 | -40.1 | 15.5 | 15.8 | 64.1 | 73.2 | 77.2 | 72.2 |
| Net Income
| -61.8 | 50.5 | 6.3 | -27.2 | -45.9 | 57.5 | 79.3 | 39.8 | -426.3 | 27.1 | 154.6 | 152.6 | 142.4 |
| Net Income Ratio
| -0.092 | 0.062 | 0.008 | -0.038 | -0.066 | 0.088 | 0.13 | 0.025 | -0.271 | 0.016 | 0.092 | 0.091 | 0.086 |
| EPS
| -1.33 | 1.08 | 0.13 | -0.57 | -0.96 | 1.22 | 1.69 | 0.85 | -9.15 | 0.58 | 3.32 | 3.28 | 3.06 |
| EPS Diluted
| -1.33 | 1.07 | 0.13 | -0.57 | -0.96 | 1.22 | 1.69 | 0.85 | -9.15 | 0.58 | 3.32 | 3.28 | 3.06 |
| EBITDA
| 50.6 | 122.9 | 47.4 | -2 | -12.1 | 41.8 | 18.9 | 153.2 | 162 | 182.6 | 297.1 | 288.2 | 265.9 |
| EBITDA Ratio
| 0.075 | 0.15 | 0.064 | -0.003 | -0.017 | 0.064 | 0.031 | 0.096 | 0.103 | 0.109 | 0.177 | 0.171 | 0.16 |